Los Angeles Capital Management LLC Buys Shares of 123,486 Aurinia Pharmaceuticals Inc $AUPH

Los Angeles Capital Management LLC bought a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 123,486 shares of the biotechnology company’s stock, valued at approximately $1,970,000.

A number of other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Aurinia Pharmaceuticals by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 1,318 shares during the period. BOK Financial Private Wealth Inc. bought a new position in Aurinia Pharmaceuticals in the fourth quarter valued at about $32,000. Concurrent Investment Advisors LLC lifted its holdings in Aurinia Pharmaceuticals by 7.8% in the fourth quarter. Concurrent Investment Advisors LLC now owns 30,270 shares of the biotechnology company’s stock valued at $483,000 after acquiring an additional 2,200 shares during the period. CWM LLC lifted its holdings in Aurinia Pharmaceuticals by 15.5% in the fourth quarter. CWM LLC now owns 16,543 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 2,225 shares during the period. Finally, IFP Advisors Inc lifted its holdings in Aurinia Pharmaceuticals by 0.9% in the third quarter. IFP Advisors Inc now owns 262,380 shares of the biotechnology company’s stock valued at $2,910,000 after acquiring an additional 2,346 shares during the period. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 0.8%

NASDAQ AUPH opened at $15.78 on Wednesday. The stock’s 50-day moving average price is $15.68 and its 200-day moving average price is $15.27. The company has a quick ratio of 5.01, a current ratio of 5.55 and a debt-to-equity ratio of 0.08. Aurinia Pharmaceuticals Inc has a 52 week low of $7.28 and a 52 week high of $16.88. The company has a market capitalization of $2.03 billion, a P/E ratio of 7.27 and a beta of 1.41.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.18 by $0.07. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%.The firm had revenue of $77.71 million for the quarter, compared to the consensus estimate of $76.98 million. On average, equities research analysts predict that Aurinia Pharmaceuticals Inc will post 0.82 earnings per share for the current year.

Insider Activity at Aurinia Pharmaceuticals

In related news, CEO Kevin Tang acquired 343,620 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were purchased at an average price of $15.28 per share, with a total value of $5,250,513.60. Following the completion of the purchase, the chief executive officer directly owned 12,838,101 shares of the company’s stock, valued at $196,166,183.28. This represents a 2.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought a total of 814,606 shares of company stock valued at $12,455,129 over the last 90 days. 12.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $17.25.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.